Money is moving again in biotech, but not for everyone. In 2025, global biotech and biopharma financing jumped to $68.5 billion. That’s up 11% from 2024, based on EY data in industry reports. But venture capital made up just $20.6 billion of that total. Most of the cash went to a handful of companies. Selectivity is fierce. EY analysis confirms it.
Chris Ehrlich, CEO of CERo Therapeutics, doesn’t sugarcoat it. He says capital strategy now matters as much as science. Flashy platforms don’t guarantee survival. Startups that treat every dollar as critical, set clear risk-cutting milestones, and build tough investor syndicates are the ones that last. The rest fall away.
In 2025, global venture funding for science-intensive startups—including AI and deep science—reached $122 billion, up 7.4% from the previous year, with large rounds increasingly concentrated in these frontier sectors.
Capital efficiency and the real threat of starvation
For early-stage biotech, the biggest risk isn’t overspending. It’s running out of cash before the science can deliver. Ehrlich has seen it firsthand. Most failures come from starvation, not excess. Capital efficiency isn’t about cutting corners. It means every dollar must cut risk or add real value to the asset. Timelines drag. Surprises are common. Discipline is non-negotiable.
Recent history made investors wary. In 2024, total biotech financing dropped about 10% to $73 billion. The first quarter of 2025 saw another 17% year-over-year drop. The bar for funding is higher now. Projects face tougher scrutiny. SRI360 analytics lays out the numbers.
Milestone-driven development and investor alignment
Investors want to know exactly how companies will use their money. Every funding round must tie to milestones that actually cut uncertainty. Not just busywork. These milestones are checkpoints. They give management and investors clear signals—go or stop. They also help with the next fundraising push.
Milestones aren’t just for tracking progress. They’re proof. Good milestones show progress in ways investors trust. That gives companies more leverage for the next round. But the standard is high. Only startups with strong data, experienced teams, and unique platforms are getting most of the new money.
In 2025, venture capital became even more concentrated among a select few companies, with deep science startups (excluding $250M+ mega-rounds) capturing 36.5% of global VC funding—nearly matching the previous year’s peak.
Building the right investor syndicate takes work. Funds have different cycles. Appetite for risk and follow-on cash varies. Management is all-in on one company. Ehrlich says early, honest talks about expectations and timelines are essential. Alignment doesn’t happen by accident. It must be built from the start. Otherwise, setbacks hit harder.
Transparency and the board as a true partner
Transparency is the last pillar. Ehrlich changed his own approach. He used to see the board as a hierarchy. Now he treats it as a partnership. That shift is spreading among biotech leaders. Boards and investors need to hear about risks and trade-offs, not just wins. Open talk lets teams make hard calls before a crisis. Boards can then back management when capital decisions get tough.
This funding surge isn’t a return to easy money. It’s selective. It’s evidence-driven. Only the best-prepared companies will make it. The lesson is clear. Capital strategy and science go hand in hand. The winners will use cash to hit real, risk-cutting milestones, build strong investor groups, and keep boards fully in the loop. In this market, discipline isn’t optional. It’s the only way good science survives.
